Cardiac Electrophysiologist• Professor• Board of Trustees HRS • #UCLA • #WomeninEP #EPeeps • #DigitalHealth •Tweets≠med advice 🏃🏻♀️🏕🏂☕️🐶🇹🇭
Coffee
Joined December 2010
- Tweets15.3K
- Following1K
- Followers8.1K
- Likes28K
Pinned Tweet
✨PUBLISHED✨
Our scientific statement
State of the Art of #ArtificialIntelligence in Clinical #Electrophysiology in 2025
We hope this new checklist helps both researchers & readers alike!
Thank you @EmmaSvennberg & @DavidDuncker for the opportunity to contribute 🙏🏼
#EHRA2025
State of the art of #ArtificiaIIntelligence in clinical electrophysiology in 2025. A scientific statement of #EHRA_ESC, the Heart Rhythm Society (HRS), and the ESC Working Group in e-Cardiology
academic.oup.com/europace/ad…
@DavidDuncker @netta_doc #Europace
JK Han MD retweeted
AF burden is increasingly being looked at as an outcome for clinical trials owing to the known limitations of time to event recurrence endpoints.
In the attached clinical trials workshop we critically examine the role of AF burden as an outcome for clinical trials of AF interventions, evaluating the evidence supporting AF burden as well as providing framework for an analytic strategy. We also delve into complementary metrics such as LEAF (longest episode of AF) and AF density.
@CardioUBC @DilawriCVI @VCHResearch
evidence.nejm.org/doi/full/1…
JK Han MD retweeted
Confusing recommendation for AF ablation in HFrEF with multiple consistent RCTs for ABL vs drugs yet LOE C! #2026ESC HF guidelines. Has there been a GDMT study in AF & HFrEF popn NOT inc substudies or secondary analysis? @drjohnm @nmarrouche @chris_sohns @escardio
JK Han MD retweeted
What's NEXT in cardiac electrophysiology and digital/Computational medicine?
AI, digital twins, bioengineering, AF/VT ablation, and wearable technologies.
Join us at Stanford Medicine, Oct 30, for EP in the West 2026—with leading innovators and rising investigators.
REGISTER👇 In person (meet and greet, networking, lunch, cookies) + free online!
stanford.cloud-cme.com/cours…
@JoseJalife4 @AndreaSarkozy steve niederer @Dr_Santangeli @igorefimov @MehakDhande @TinaBaykaner @EldrinL @Wanginnovate @DrJackOSullivan @euanashley @StanfordHAI
JK Han MD retweeted
Interesting piece. One question from the EP side: if interventional HF encompasses TEER, MCS, CCM, etc., shouldn’t CRT/CSP—one of the great success stories in HF—have a more central place? And if @HFSA @SCAI will co-own this emerging field, shouldn’t EP @HRSonline have a seat at the table?
Excellent statement on the journey so far and path forward toward interventional heart failure (IHF) as a discipline. Worth a read.
Link: sciencedirect.com/science/ar…
Title ⬇️
JK Han MD retweeted
Day one at #HRX2026 @experienceHRX is in the books! Looking forward to the next two days of this intentionally unconventional conference. Be there! #EPeeps
That's a wrap on Day 1 of HRX Live 2026! The Innovation Summit, our first Main Tent speaker, the opening pitch competition presentations — and we're just getting started. Stay tuned! More #HRX2026 coverage is coming your way, #EPeeps.
@MehakDhande
@OliverMonfredi
@Nashwa_Salem_
JK Han MD retweeted
Join the AP shark tank on main stage 1 #HRX2026 starting now
Judges @netta_doc geraldine Lee & moderators @J_Hendriks1 Brynn Dechret #HRX 2026
JK Han MD retweeted
#HRX2026 AP sharktank is underway! Can we use AI to assit in MRI non conditional devices to MRI?
JK Han MD retweeted
Very important message from our group. In patients with recurrent AF after a first ablation, what we do next matters. Repeat catheter ablation was associated with a 35% lower risk of death, stroke, or HF hospitalization compared with cardioversion, with an NNT of only 14.
This challenges the idea that management of recurrent AF should simply be based on operator preference. Recurrence after ablation should not be viewed as failure—it may be an opportunity to intervene again and improve meaningful clinical outcomes.
Congratulations to @mabou_khalil @HanFengGHD @QMarashly and the entire team. #AFib #Ablation #EPeeps
@PrashSanders @shivkumarmd @gautamsand @S_NarayanMD @Phiso_de @drsuneet @drjohnm @drluissaenz @leftbundle @KennethEllenbo1 @DrBradleyKnight @DrRoderickTung @atulverma_md
AF recurs in up to 50% post-ablation, what's next is often just operator preference. Our study in Europace of 3,100+ patients: redo ablation cut death/stroke/HF by 35% vs. cardioversion (NNT=14). 🫀⚡
@nmarrouche @HanFengGHD @QMarashly
📄 doi.org/10.1093/europace/eua…
#AFib #EPeeps
JK Han MD retweeted
Bring your team to #WAFIB2027 for live cases, interactive debate, & practical insights spanning ablation, stroke prevention, PFA, LAAO, imaging, AI, & more.
$100 Off with Code AWARENESS: hubs.ly/Q04w-2ss0
@nmarrouche @EPLabDigest
JK Han MD retweeted
Important PVI-SHAM-AF trial—but interpretation matters. This was not ablation vs “nothing.” The sham arm included deep sedation, an invasive cath-lab procedure, intensive follow-up and, importantly, cardioversion when patients were in AF—itself an effective rhythm-control intervention.
Yet ablation still produced substantially better rhythm control (73% vs 52% freedom from AF).
With QoL assessed at only 6 months, are we measuring the effect of ablation—or comparing two active rhythm-control strategies?
I would be cautious concluding that ablation does not improve symptoms. The study may instead demonstrate how difficult it is to design a truly inert sham for AF.
#AFib #CatheterAblation #RhythmControl #PVI #ESCCongress @PrashSanders @drjohnm @chris_sohns @peterkistler3 @DJ_Lakkireddy @DrRoderickTung @TinaBaykaner @DrJasonAndrade @SteffelJ @netta_doc @TulaneHeart
One of the #ESCCongress highlights:
#HOTLINE #LBCT
PVI-SHAM-AF
🫀262 patients (~1/2 women! 👏🏽)with symptomatic AF → ablation vs sham
🫀At 6 mo, AF-related QoL improved in BOTH groups, with no significant benefit from ablation (P=.36)
🫀But ablation improved freedom from AF: 73% vs 52%.
Better rhythm control ≠ necessarily better QoL @RoWachter
I love the sham trials!
Lancet: doi.org/10.1016/S0140-6736(2…
JK Han MD retweeted
How low should we go with BP in atrial fibrillation?
Our #ESC2026 study, simultaneously published in @EuropaceEiC , suggests a “sweet spot”:
🔹 SBP ~120–130 mmHg
🔹 Avoid DBP <75–80 mmHg
🔹 Lower is not always better
In AF, both numbers matter.
bit.ly/4yeNyQB
#AtrialFibrillation #Hypertension
@ElnazShmohamadi @melissaemm1 @Elliott_AD @JonathanAriya
JK Han MD retweeted
ENRICH-AF trial: In AF patients with prior ICH, edoxaban did not lower stroke or systemic embolism but increased major bleeding compared to non-anticoagulant therapy. Download slides here: clinicaltrialresults.org/wp-…
JK Han MD retweeted
EPIDAURUS trial: In patients with AF and ACS, dual antithrombotic therapy with DOAC and intensified P2Y12-inhibition with prasugrel or ticagrelor for 1 month was associated with a higher bleeding risk without reducing ischemic events compared to triple antithrombotic therapy. Download slides here: clinicaltrialresults.org/wp-…
JK Han MD retweeted
New consensus in #Europace 📢
Diagnosis and Management of Very Rare Primary Arrhythmia Syndromes in Children and Adults 🧩💔
@JacobTfelt @amazzanti79 @arbelo_e @GiulioConteMD @BehrElijah @CrottiLia @J_Hendriks1 @ArthurWilde5 @MJAckermanMDPhD
🔗doi.org/10.1093/europace/eua…
JK Han MD retweeted
📣 NEW CONSENSUS DOCUMENT
Just published on #Europace
Workup and management of rhythm disorders in myocarditis and inflammatory cardiomyopathy ⚡️
🔗 doi.org/10.1093/europace/eua…
@EHRAPresident @HFA_President @HRSonline @APHRSOfficial @LAHRSonline1 @GiovanniPeretto
#ESCCongress
JK Han MD retweeted
📢 New in #Europace | #ESCCongress
In 476,750 AF patients:
🔹 Lowest mortality around SBP 134 / DBP 83 mmHg
🔹 Stroke and ICH increased with higher SBP
Pragmatic target: SBP 120–130, avoid DBP <75–80 mmHg 📊
🔗 doi.org/10.1093/europace/eua…
@PrashSanders @ElnazShmohamadi
JK Han MD retweeted
#CMRGUIDE at #ESCCongress
Should myocardial SCAR—not just EF—help determine who gets a primary-prevention ICD?
Patients with:
➡️ LVEF 36–50%
➡️ Ischemic or nonischemic cardiomyopathy
➡️ Scar/fibrosis on CMR
Randomized 353 pt, impacted by COVID, 82% Men
⏱️6.3 y
ICD vs implantable loop recorder
Primary Endpoint= SCD or hemodynamically significant ventricular arrhythmia
🌟RESULTS:
Primary: SCD or hemodynamically significant ventricular arrhythmia
➡️ HR 0.76 (95% CI 0.37–1.58), P=.47 ❌
Sudden cardiac death alone:
➡️ HR 0.26 (0.07–0.95), P=.04
All-cause mortality:
➡️ HR 0.91 (0.49–1.71), P=.78
🫀 CMR-guided ICD implantation did not reduce the primary composite endpoint. The reduction in SCD is intriguing, but as a secondary endpoint in a negative trial it should be interpreted cautiously.
CMR scar alone does not yet appear sufficient to expand ICD indications beyond current EF-based criteria.
📄 jamanetwork.com/journals/jam… @JAMA_current
#WhyCMR #CardioTwitter #EPeeps #HeartFailure
Fun session to start off #ESCCongress2026!
An honor to join amazing friends from around the world for “#Artificialintelligence in #AFib care: smarter detection, safer treatment, better outcomes?” chaired by Drs. @g_andre_ng & Isabel Deisenhofer
Thanks @escardio for the invite!
JK Han MD retweeted
Presented at #ESCCongress:
In patients with atrial fibrillation and intermediate stroke risk, direct oral anticoagulation led to a lower risk of stroke, systemic embolism, major bleeding, or death from cardiovascular causes than no anticoagulation. Full SINGLE-AF trial results: nej.md/4ii61XB
Editorial: Anticoagulation for Atrial Fibrillation with a Single Risk Factor for Stroke nej.md/45FR7D4
@escardio
ALT A graph from the Original Article "Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk." The trial name, SINGLE-AF, is in parentheses after the title. The graph shows the cumulative incidence of primary end-point events (intention-to-treat population). The trial results are being presented at the European Society of Cardiology Congress 2026. The logo of the New England Journal of Medicine is at the bottom.
JK Han MD retweeted
This is an incredibly important study.
The just presented SINGLE-AF trial randomised patients with a single risk factor (other than sex), demonstrating a significant reduction in stroke, systemic embolism, major bleeding, or death from cardiovascular causes at 24 months.
Although the @SCC_CCS AF guidelines (onlinecjc.ca/article/S0828-2…) have advocated for OAC for this group of patients for many years, sometimes at contrast with other national societies, its nice to see that this approach has been validated in a large RCT.
nejm.org/doi/full/10.1056/NE…
